Percutaneous Replacement Disc Nucleus (PRDN)
The PRDN is a device which is competing in the treatment of back pain in a sector referred to as "motion preservation". It is implanted via a minimally invasive technique and replicates the function of a healthy spinal disc.
Low back pain or spinal pain is a major cause of worldwide disability and loss of time from work, causing a major drain on a countrys economy. The cost to healthcare systems is enormous in terms of treatment, long hospital stays and the high cost of medication.
In addition to the natural aging process hereditary factors, biochemical factors and repetitive injury, leads to degenerate of discs, this can lead to a disc herniation causing sciatica; or simply chronic back pain, or both. There is a degenerative cascade where the degree of degeneration relative rest, anti-flammatory pain killing medication, physiotherapy with a graded return to normal activities are used to aid the bodys natural healing processes; surgery is used when these fail.
Different types and degrees of degeneration require different approaches to treatment ranging from simple removal of a herniation, to spinal fusion and stabilization procedures which result in reduced movement of the affected disc or spinal segment. This has a significant effect on the movement of the remaining spine, particularly the segment next to the fusion. The trend is now to develop treatments that preserve movement to allow the rest of the spine to move normally reducing the likelihood of future problems.
Epsicom conducted a market research report in 2007 on spinal orthopaedics and stated that "Motion preservation is the hottest topic around in spinal orthopaedics - a sector forecast to achieve 16% growth per year and revenues of US$5.1 billion by 2011. By that time, motion preservation technologies (such as PRDN) will achieve and account for 50% fo the market."
The PRDN offers veral clinical benefits and offers several advantages over existing products. The device replicates the biomechanical function of the healthy disc therefore there should be a return to near normal activity for the patient and it is expected that patient time within the hospital would be dramatically reduced. The device will not migrate and dislodge from the disc nucleus site unlike other devices making it an appealing alternative. Additionally the PRDN provides support to annulus.
Prototypes have been built and tested and commercial design completed. SHIL is offering commercial opportunities to help prepare the product for clinical trial and take the product to market.